We must invest much more in the diagnosis and treatment of chronic obstructive pulmonary disease
Sponsored by Aga Khan University Hospital
By Dr Jumaa Bwika
Every November 20 since 2002, we mark the World COPD Day to raise awareness about Chronic Obstructive Pulmonary Disease, which is the fourth leading cause of death globally according to the World Health Organisation (WHO).
COPD is an incurable condition resulting from irreversible damage of the airways and the air sacs of the lungs. Often times, this is caused by long term smoking of tobacco, shisha and vaping, and sustained breathing of other organic or inorganic pollutants. Further to being incurable and irreversible, this damage is progressive with continued exposure to the noxious agents.
There is increasing awareness that tuberculosis of the lung, even when completely and effectively treated, results in COPD and other lung diseases amongst survivors. COPD disease causes clogging of the airways, hence a cough that never goes way, and which may produce mucoid phlegm or sputum. There may be breathlessness, initially with significant exertion, but that may insidiously worsen over time to eventually cause disability.
Chest infections, which usually represent flare-ups of this lung disease, feature repeatedly over time as the lungs become increasingly vulnerable. There may be wheezing or other types of noisy breathing, and eventually patients waste away and develop many different complications affecting the heart and other vital bodily functions. It is the eighth biggest cause of poor health in the world.
The occurrence of two or more of these symptoms in people who have had consistent exposure to cigarette smoke, even passively, or other causes, usually increases suspicion of COPD. Definite diagnosis requires measurement of specific parameters of air flow during forceful breathing using a test called spirometry, by trained healthcare professionals.
It is estimated that about 64 million people in the World currently suffer from this devastating disease. A recent review of COPD in Ethiopia, Sudan, Malawi, Kenya, Uganda and Tanzania found that it affects between seven to about 19 percent of East Africans, and is as frequent as 11.3 percent in Kenya. In high income countries, more than 70 percent of COPD is caused by smoking of tobacco, whilst this number drops to between 30 and 40 percent in low and middle income countries where pollution from burning biomass fuels like firewood, charcoal and kerosene has been postulated as an important cause. Poor air quality amongst quarry workers, miners and other occupational exposures to organic and inorganic air pollutants contribute to COPD.
At the height of the Covid-19 pandemic, COPD was the fourth biggest cause of death in the world behind heart disease, stroke and Covid-19, accounting for 3.5 million deaths. This magnitude of mortality has been consistent and increasing in the past decade, with expectations that it shall be the third-biggest cause of death in the next six years. Sadly, almost 90 out of every 100 of these deaths for people aged less than 70 years occur in low and middle income countries.
Management of COPD must of necessity begin with a clean break from exposure to the causative factors. Important lifestyle changes beyond this include healthy diets and regular exercise to improve fitness and breathing, and to retain muscle strength. Specific treatment involves consistent use of treatments that dilate the clogged airways to reduce cough and breathlessness. Steroids, in appropriate doses, have an important but niche role in managing flare ups and reducing infections. This role is significantly less than the central role they play in management of asthma.
There are other medicines that reduce the tenacity and amount of sputum production. Some medicines are used to reduce airway and lung inflammation in a select group of COPD patients. Antibiotics may be prescribed when bacterial infections are responsible for a flare-up.
Vulnerability to infections is reduced with vaccinations against influenza, and against the commonest bacterial cause for respiratory infections. Most of these medicines are delivered into the body using inhalers, which are rather smart and often easy to use devices. They deliver miniscule doses of medication using the breath as a courier, hence efficiently and effectively depositing the drug to most of the diseased airway and lung tissue whilst minimising side effects. It is important to point out that these treatments are necessary when prescribed, but they are not addictive at all, hence there is no development of dependence.
Given the prevalence of COPD including here in Kenya, its importance as a major cause of death and poor health, it is of big concern that public awareness of this disease is appallingly low. Definite diagnosis requires the use of spirometry equipment by specially trained personnel, both of which are not readily accessible to the majority of Kenyans. Further, most of the effective treatments are out of reach to those who need them most.
We must do more to increase correct diagnosis of all COPD in Kenya, and increase the affordability and accessibility of effective treatments to all Kenyans.
____________________
Dr Jumaa Bwika is a Consultant Pulmonologist at Aga Khan University Hospital in Nairobi
